



*Pedal wound and diabetes management is an ever-growing aspect of podiatric practice, and is of particular importance in helping to confirm and maintain the idea of DPMs as integral members of the typical multidisciplinary “wound care team.” Here we present a sampling of both new and established wound care-related products and services available to the podiatric community.*

## Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care

MIMEDX Group, Inc. is excited to share another addition to their portfolio of clinical research with the publication of a peer-reviewed study in the *Journal of Wound Care (JWC)* evaluating the cost-effectiveness of PURION® processed DHACM allografts compared with standard of care in treating Lower Extremity Diabetic Ulcers (LEDU).



**NEW PEER-REVIEWED STUDY**

Those living with diabetes and suffering from LEDUs face multiple morbidities and costs, significantly impacting their quality of life. MIMEDX, is committed to expanding their research to improve people’s health and lives

To read the full press release, click here. For additional information about the MIMEDX full portfolio of products, please visit [www.MIMEDX.com](http://www.MIMEDX.com)



*Continued on page 88*

## Oxygen Therapy and NPWT Systems from AOTI

AOTI’s mission is to help all people with chronic conditions get back to living life to the fullest. They are committed to enhancing access to care, improving quality of life, and advancing health equity.

AOTI offers a multi-modality topical wound oxygen therapy proven in both randomized controlled trials and real-world evidence studies to significantly reduce wound reoccurrence, hospitalizations and amputations. The therapy uses a combination of non-contact cyclical compression, higher-pressure oxygen and humidification, applied directly to the wound. In DFUs, TWO2 therapy has demonstrated an 88% reduction in hospitalizations and 71% reduction in amputations over 12 months. The therapy can be utilized in any clinical setting and is commonly administered



by patients at home. This helps to improve therapy compliance and improves access to care, while enhancing health equity and clinical outcomes, and reducing costs.

For patients requiring negative pressure wound therapy, the AOTI’s NEXA™ NPWT System provides uncompromising treatment for patients with chronic and acute wounds. This multi-week, multi-patient, disposable system is simple, silent, portable and affordable. The NEXA System has no complicated interfaces or touchscreens. It runs smoothly and consistently without nuisance alarms. It is lightweight, compact, with a handy carrying case and 10-hour battery life. The NEXA System is designed to operate for 8 weeks (56 days). Usable hours are depleted only when the device is providing therapy; remaining hours can be used at your convenience on the next patient.

Visit [aotinc.net](http://aotinc.net) or click here.



**FDA cleared and CE marked for the treatment of Acute and Chronic wounds**

**MULTI-MODALITY TWO2 WORKS LIKE NO OTHER**



### OXYGEN

High-pressure delivery results in greater tissue diffusion critical to restoring normal wound metabolism, resulting in **more effective and durable healing.**



### COMPRESSION

Non-contact cyclical compression addresses edema and **helps correct the underlying peripheral vascular disease.**



### HUMIDIFICATION

Assures an ideal wound healing environment, promoting healthy granulation tissues for **faster, more effective and durable healing.**





## Erchonia's Lunula Laser Offers Powerful Alternative to Traditional Nail Fungal Treatments

Erchonia Corporation's non-thermal Lunula Laser is FDA-cleared for promoting new clear nail growth in individuals with onychomycosis. The Lunula Laser presents a safe, powerful and effective alternative to traditional treatments, completely avoiding the possible risks of oral anti-fungal medications.

The Lunula advantage stands out in its unique features:

- No heat, pain, or downtime
- 6.1 mm of new clear nail growth at 6 months
- 12-minute treatments
- Ability to treat all 5 toes at once
- FDA cleared.

The Lunula Laser targets fungus both in and under the toenail without damaging the nail or surrounding skin. A mere four 12-minute sessions are typically all that's needed to treat the affected area, with no recovery time required.

Erchonia's innovative technology employs a patented red and violet laser that provides a multifaceted approach to low-level laser therapy via two different wavelengths to the affected area. Photonic energy is utilized to modulate cellular reactions that specifically target the fungus without any adverse reactions to the nail bed, toe, or foot.

Lunula maintains the highest safety standards and has been rigorously tested



for effectiveness and safety. Given the use of extremely low wavelengths and power, most patients experience no discomfort, burning, or pain. This treatment is performed while patients are awake, reducing downtime and allowing them

*Continued on page 89*

## EO2 Announces International Recognitions

EO2 Concepts® has announced that their Continuous Diffusion of Oxygen (CDO) Therapy has been internationally recognized as standard of care, adding to the growing list of advocacies and evidence in the therapy's favor.

The International Working Group on the Diabetic Foot (IWGDF) and the American Diabetes Association

mended standards of care are huge steps forward."

Through an equity crowdfunding campaign on StartEngine, EO2 is enabling smaller individual investors to participate in this large growth opportunity. The company is broadening access of their advanced oxygen-enhanced technology in the medical community and developing new product solutions as they become a leading standard of care for advanced wound healing and skin support. *To learn more details about EO2 or how to invest through StartEngine go to: <https://www.startengine.com/eo2> or click here.*

### About EO2®

EO2 Concepts® is a privately held advanced wound care technology company based in San Antonio, TX. As the developer and manufacturer of a disruptive, FDA-cleared medical device, they provide CDO Therapy which continuously delivers oxygen to tissues. Their flagship OxyGeni® System continuously produces oxygen directly from air and delivers the pure, humidified oxygen to target tissues, such as those with a wound or compromised skin, using an oxygen diffusion dressing. The system is able to monitor conditions within the dressing to ensure efficacious delivery of oxygen. CDO Therapy has been shown to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain and minimizing the formation of scar tissue in the process.

**Invest in EO2 Today**



(ADA) have recently added CDO Therapy as a standard of care for the treatment of diabetic foot ulcers. Both recognitions add a substantial weight to the already heavy list of evidence backing the therapy. With multiple meta-analyses, systematic reviews and a Delphi consensus guidance document published last year, the list of supporting evidence and new advocacies have grown substantially.

"We are excited to witness the rapidly growing adoption of CDO therapy in multiple, high growth markets," said President and CEO Mark Q. Niederauer, PhD. "Having high level, internationally recognized medical organizations and peer-reviewed publications add our innovative CDO therapy to their lists of recom-



to continue with their day effortlessly.

The device is equipped with 2 class 2 Line Generated Laser Diode Modules, with wavelengths of 640nm & 405nm. Other key specifications include a Full Color TFT Touch Screen Control Center, a powder-coated aircraft aluminum chassis, and a 304 stainless steel treatment area for anti-microbial properties. The Lunula Laser complies with ISO 13485 Medical Device Quality, ISO 14971 Risk Management, IEC 60825-1 Laser Safety, IEC 60601-1 MEE Safety, and IEC 60601-1-2 EMC.

For more information, please visit <https://www.lunula.com/home/> or click here.

## APWH Verifies Industry's First Comprehensive Skin and Wound Care Guidelines Manual

The Academy of Physicians in Wound Healing (APWH), one of the leading worldwide professional associations dedicated to improving the lives of patients with complex chronic wounds, announced they have verified *The Skin and Wound Care Guidelines Manual* published by NMwoundcare.

The comprehensive manual is a result of thousands of hours of research, compiled into a complete collection of clinical education guidelines, facility policies and procedures, professional forms, and an on-demand educational series.

"Nothing has been published in this market so exhaustive and complete. This manual was written from the most current standards of care and will provide the guiding principles for clinicians to deliver consistently high-quality care to our most deserving patients," said Nancy Morgan, RN, BSN, MBA, WOC, President and Founder of NMWC.

**About APWH:** APWH's mission is to promote wound healing as a specialized field of medicine and to empower their members to become leaders in the science and practice of wound care.

**About Nancy Morgan Wound Care (NMWC):**

NMWC develops professional wound care education solutions through several avenues such as webinars, courses, conferences, and

## APWH Academy of Physicians in Wound Healing

consulting. Morgan is the principal of Nancy Morgan Wound Care and former owner and CEO of Wound Care Education Institute and Wild on Wounds convention.

Visit [APWH.org](http://APWH.org) for more information or click here.



## NATROX® Wound Care Celebrates Global Recognition of Topical Oxygen Therapy for Chronic Wounds

NATROX® Wound Care, a leading provider of wound care solutions, is proud to announce the ongoing global recognition of topical oxygen therapy as a highly effective treatment for chronic wounds. The groundbreaking NATROX® O<sub>2</sub> Continuous Topical Oxygen Therapy (cTOT) has gained significant acclaim from prestigious organizations and experts worldwide.

The American Diabetes Association<sup>1</sup>, the International Working Group on the Diabetic Foot (IWGDF)<sup>2</sup>, and esteemed experts in Central and Eastern Europe (CEE)<sup>3</sup> have all recently released recommendations endorsing topical oxygen therapy as a treatment for chronic wounds in their

respective regions. This recognition affirms the immense potential and transformative impact of NATROX® O<sub>2</sub> on wound care management.

According to Dr. Windy Cole, DPM, CWSP, FAPWH, FACCWS, a renowned authority in podiatric medicine and dedicated wound care advocate for over two decades, "The evidence supporting the efficacy of TOT is now undeniable. It is imperative that healthcare professionals worldwide embrace this innovative yet simple approach to achieve improved healing outcomes." Dr. Cole recently joined the NATROX® Wound Care team as Director of Global Medical Affairs to further advocate for the integration of topical oxygen therapy in the treatment pathway for chronic wounds.

### About NATROX® Wound Care

NATROX® Wound Care is a renowned global provider of innovative wound care solutions. By developing technologically advanced, cutting-edge products and educational resources, the company aims to revolutionize the management of chronic wounds globally. NATROX®

Wound Care's flagship product, NATROX® O<sub>2</sub>, delivers continuous topical oxygen therapy to promote the healing of non-healing wounds. Committed to excellence, NATROX® Wound Care continually strives to enhance the quality of life for individuals affected by chronic wounds.

Visit [natroxwoundcare.com](http://natroxwoundcare.com) or click here.

### References

<sup>1</sup> American Diabetes Association. (2023) Standards of Care in Diabetes-2023, Diabetes Care, 46(S1):S209-12.

<sup>2</sup> International Working Group on the Diabetic Foot-IWGDF. (2023) Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF Guidelines, May 2023.

<sup>3</sup> Bem R, Chadwick P, Cvjetko I, et al. (2023) A new algorithm for the management of diabetic foot ulcer: recommendations from Central and Eastern Europe. J Wound Care, 32(5):264-72.